Head-to-head comparisons of medication uses, side effects, warnings, and more.
Inpefa (sotagliflozin)
Jardiance (empagliflozin)
Inpefa (sotagliflozin)
Jardiance (empagliflozin)
Summary of Inpefa vs. Jardiance
Summary for SGLT1/SGLT2 inhibitor
Prescription only
Inpefa (sotagliflozin) is a newer medication that's approved to lessen the risk of heart-related complications in people with heart failure and in people with Type 2 diabetes, chronic kidney disease (CKD), and other heart-related conditions. This medication comes as a tablet that you take by mouth once daily. Side effects can include urinary tract infections (UTIs) and diarrhea. Inpefa (sotagliflozin) is expected to be available in the U.S. in summer 2023.